Dyne Therapeutics DYN
NASDAQ DYN
$15.20 -0.62 (-3.92%)
At close: Oct 2, 2026 · 4:00 PM EDT

Dyne Therapeutics (DYN) Gains from Sales and Divestitures (2023 - 2026)

Updated

Dyne Therapeutics (DYN) reported Gains from Sales and Divestitures of -$30,000 for Q1 2026, compared with -$95,000 a year earlier.

Analysis

Dyne Therapeutics (DYN) Gains from Sales and Divestitures (2023 - 2026) Analysis & Trends

For FY2025, Dyne Therapeutics posted Gains from Sales and Divestitures of -$95,000.

  • By year, Gains from Sales and Divestitures came in at -$72,000 in FY2024 and -$118,000 in FY2023.
  • The Q1 2026 figure ranks as the highest quarterly Gains from Sales and Divestitures since Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Dyne Therapeutics 2.52 Bn 2.52 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -30,000.00
Mar 31, 2025 -95,000.00
Dec 31, 2024 -74,000.00
Mar 31, 2024 2,000.00
Mar 31, 2023 -118,000.00
API Access

Dyne Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=DYN&period=max&api_key=YOUR_API_KEY